Amgen Scholar engages in anti-cancer research
Sara Journey began developing her undergraduate research training at SDSU June 2014 in the Department of Chemistry and Biochemistry. In June 2016, Sara was accepted as an Amgen Scholar at the University of California, San Francisco designing anti-cancer molecular compounds that bind to the stress-inducible chaperone heat shock protein 70 (Hsp70), then observing the chaperone's affect on protein homeostasis within cells. Even though the cycle of developing cancer therapeutics is long and challenging, Sara and her colleagues hope to discover innovative inhibitors of neurodegeneration and cancer diseases so that they may be brought to clinical trial research. Her research UCSF can provide oncologists with a new method for cancer inhibition, generating an arsenal of new protein pathways that can be therapeutic targets, which hinders cancer metastasis. In the future, Sara wants to gain an MD/PhD degree so that she may continue to pursue her interest in oncology, while working with clinical trial patients.